![Joël Jean-Louis Besse](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Joël Jean-Louis Besse
Directeur Général chez
Pharma Group Santé SAS
Profil
Joël Jean-Louis Besse is currently the Chief Executive Officer at Pharma Group Santé SAS and the Director at U3 Pharma AG since 2009.
Previously, he served as the Chairman at NFL Biosciences SAS from 2018 to 2023.
He has also held director positions at various companies including Prestwick Pharmaceuticals, Inc., FIBREX Medical, Inc., Xytis, Inc., Novuspharma SpA, Arrow Therapeutics Ltd., Immuno-Designed Molecules SA, Neurotech Pharmaceuticals, Inc. (United States), Novexel SA, Newron Pharmaceuticals SpA, Actelion Pharmaceuticals UK Ltd., Entomed SA, Arthur Andersen LLP, Atlas Venture LLP, Axovan AG, and Horizon Therapeutics Switzerland GmbH.
Mr. Besse completed his undergraduate studies at Université Fédérale Toulouse Midi-Pyrénées and École Nationale Supérieure de Aéronautique et de l’Espace.
Postes actifs de Joël Jean-Louis Besse
| Sociétés | Poste | Début |
|---|---|---|
U3 Pharma AG
 U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services Researches and develops novel targeted therapeutics used for cancer treatment | Directeur/Membre du Conseil | - |
Pharma Group Santé SAS
 Pharma Group Santé SAS Medical DistributorsDistribution Services Distributes and sells pharmaceutical products | Directeur Général | - |
Anciens postes connus de Joël Jean-Louis Besse
| Sociétés | Poste | Fin |
|---|---|---|
| NFL BIOSCIENCES | Président | 27/02/2023 |
FIBREX Medical, Inc.
 FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services Provides bio-pharmaceutical research development services | Directeur/Membre du Conseil | 05/02/2013 |
| NEWRON PHARMACEUTICALS S.P.A. | Directeur/Membre du Conseil | 17/11/2006 |
Novuspharma SpA
 Novuspharma SpA Pharmaceuticals: MajorHealth Technology Researches treatments for cancer and develops pharmaceuticals related to cancer treatments | Directeur/Membre du Conseil | 01/01/2004 |
Neurotech Pharmaceuticals, Inc. (United States)
 Neurotech Pharmaceuticals, Inc. (United States) Pharmaceuticals: MajorHealth Technology Designs and develops therapeutic systems for retinal diseases | Directeur/Membre du Conseil | - |
Formation de Joël Jean-Louis Besse
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
9
Relations au 1er degré
20
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 20 |
|---|---|
Prestwick Pharmaceuticals, Inc.
 Prestwick Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for diseases related to the central nervous system | Health Technology |
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services Provides bio-pharmaceutical research development services | Commercial Services |
Xytis, Inc.
 Xytis, Inc. BiotechnologyHealth Technology Develops & discovers CNS drug candidates | Health Technology |
Novuspharma SpA
Novuspharma SpA Pharmaceuticals: MajorHealth Technology Researches treatments for cancer and develops pharmaceuticals related to cancer treatments | Health Technology |
Arthur Andersen LLP
 Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Provides accounting services | Commercial Services |
Arrow Therapeutics Ltd.
 Arrow Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
Immuno-Designed Molecules SA
 Immuno-Designed Molecules SA Pharmaceuticals: MajorHealth Technology Specializes in biopharmaceutical products with focus in immunotherapy for the treatment of cancer | Health Technology |
Atlas Venture LLP
 Atlas Venture LLP Investment ManagersFinance Atlas Venture is a leading international venture capital investment manager specialized in sectors including life sciences, communications and information technology and investing in Europe and the US. The firm targets early-stage, science-based businesses and leads the first financing round, generally acquiring a significant minority stake which grants them board representation. They subsequently help recruiting a management team to carry the emerging business forward, typically towards international expansion. Atlas Venture also invests in later-stage operations such as corporate spin-offs and down financing. Investment criteria include leadership potential in a global high-growth market, market momentum and a proprietary disruptive technology or business model. In the technology industry, Atlas Venture focuses on components, systems, software and services. The group has invested in data warehousing, storage systems for digital media, core chips for mobile phones and MEMS-based displays for mobile devices. Their biotechnology investments focus on drug discovery. They have invested in blood-thinning agents, small interfering RNA, emerging cancer drugs and anti-infectives. Atlas Venture sources deals though a combination of top-down global market analysis and bottom-up local connections in their industries of choice, including contacts in the academic world. Their exit strategies are international and include M&A transactions and IPOs on a variety of exchanges. | Finance |
Neurotech Pharmaceuticals, Inc. (United States)
Neurotech Pharmaceuticals, Inc. (United States) Pharmaceuticals: MajorHealth Technology Designs and develops therapeutic systems for retinal diseases | Health Technology |
Axovan AG
 Axovan AG Miscellaneous Commercial ServicesCommercial Services Discovers and develops drugs | Commercial Services |
Novexel SA
 Novexel SA Pharmaceuticals: MajorHealth Technology Researches and develops anti-infective drugs for the treatment of bacterial and fungal infections | Health Technology |
Newron Pharmaceuticals SpA
 Newron Pharmaceuticals SpA Pharmaceuticals: MajorHealth Technology Develops and sells novel therapies central & peripheral nervous system | Health Technology |
Horizon Therapeutics Switzerland GmbH
 Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Discovers and develops medicines for the treatment of chronic inflammatory diseases | Health Technology |
U3 Pharma AG
U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services Researches and develops novel targeted therapeutics used for cancer treatment | Commercial Services |
Actelion Pharmaceuticals UK Ltd.
 Actelion Pharmaceuticals UK Ltd. Medical DistributorsDistribution Services Discovers, develops and markets drugs | Distribution Services |
Entomed SA
 Entomed SA Pharmaceuticals: MajorHealth Technology Discovers and develops anti-infective drugs derived from insects | Health Technology |
Université Fédérale Toulouse Midi-Pyrénées
 Université Fédérale Toulouse Midi-Pyrénées Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
École Nationale Supérieure de Aéronautique et de l’Espace
 École Nationale Supérieure de Aéronautique et de l’Espace Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pharma Group Santé SAS
Pharma Group Santé SAS Medical DistributorsDistribution Services Distributes and sells pharmaceutical products | Distribution Services |
NFL Biosciences SAS
 NFL Biosciences SAS BiotechnologyHealth Technology Operates as a biotechnology company that develops botanical treatments for addictions | Health Technology |
